Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 6/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | AKT2 | P31751 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13836819 | 0.77 | KMT2A (0.49) | KMT2AMEN1KDM4EPKML3MBTL1 | |
| SCHEMBL1102422 | 0.76 | TDP1 (0.55) | KMT2AMEN1KDM4EPKML3MBTL1 | |
| SCHEMBL3661077 | 0.76 | TDP1 (0.55) | KMT2AMEN1KDM4EPKML3MBTL1 | |
| SCHEMBL14923045 | 0.75 | KDM4E (0.50) | KMT2AMEN1KDM4EPKML3MBTL1 | |
| SCHEMBL29382173 | 0.73 | KDM4E (0.74) | KMT2AMEN1KDM4EPKMADORA2A | |
| SCHEMBL732131 | 0.73 | KDM4E (0.74) | KMT2AMEN1KDM4EPKMADORA2A | |
| SCHEMBL24702664 | 0.73 | TDP1 (0.56) | KMT2AMEN1KDM4EPKML3MBTL1 | |
| SCHEMBL3579261 | 0.72 | ADORA2A (0.59) | KMT2AMEN1ADORA2ALMNANPSR1 | |
| SCHEMBL28710728 | 0.71 | KDM4E (0.71) | KMT2AMEN1KDM4EPKMADORA2A | |
| SCHEMBL865711 | 0.71 | KDM4E (0.71) | KMT2AMEN1KDM4EPKMADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2061764-B1 | HETEROCYCLIC DERIVATIVES BINDING TO THE PERIPHERAL-TYPE BENZODIAZEPINE RECEPTOR (PBR) | TECHNION RES & DEV FOUNDATION (IL) | 2014-07-02 | — | — | EP | disclosed |
| US-8541428-B2 | Heterocyclic derivatives, pharmaceutical compositions and methods of use thereof | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2013-09-24 | — | — | US | disclosed |
| US-8541428-B2 | Heterocyclic derivatives, pharmaceutical compositions and methods of use thereof | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2013-09-24 | — | — | US | disclosed |
| EP-2589597-A2 | Heterocyclic derivatives binding to the peripheral-type benzodiazepine receptor (PBR) | Technion Research & Development Foundation (IL) | 2013-05-08 | — | — | EP | disclosed |
| US-20100029658-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2010-02-04 | — | — | US | disclosed |
| US-20100029658-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2010-02-04 | — | — | US | disclosed |
| EP-2061764-A1 | HETEROCYCLIC DERIVATIVES BINDING TO THE PERIPHERAL-TYPE BENZODIAZEPINE RECEPTOR (PBR) | Technion Research & Development Foundation LTD. (IL) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008023357-A1 | HETEROCYCLIC DERIVATIVES BINDING TO THE PERIPHERAL-TYPE BENZODIAZEPINE RECEPTOR (PBR) | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029658-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | NQO1, SIRT5, KEAP1 | KMT2A 2240/4885MEN1 1210/4885KDM4E 1814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.